The Aβ42:Aβ40 ratio modulates aggregation in beta-amyloid oligomers and drives metabolic changes and cellular dysfunction

Front Cell Neurosci. 2024 Dec 5:18:1516093. doi: 10.3389/fncel.2024.1516093. eCollection 2024.

Abstract

The pathophysiological role of Aβ42 oligomers in the onset of Alzheimer's disease (AD) is heavily disputed, pivoting research toward investigating mixed oligomers composed of Aβ42 and Aβ40, which is more abundant but less aggregation-prone. This study investigates Aβ42:Aβ40 oligomers in different ratios, examining their adverse effects on endothelial cells, neurons, astroglia, and microglia, as well as in a human blood-brain barrier (BBB) model. Combining label-free Raman microscopy with complementary imaging techniques and biochemical assays, we show the prominent impact of Aβ40 on Aβ42 fibrillation, suggesting an inhibitory effect on aggregation. Mixed oligomers, especially with low proportions of Aβ42, were equally detrimental as pure Aβ42 oligomers regarding cell viability, functionality, and metabolism. They also differentially affected lipid droplet metabolism in BBB-associated microglia, indicating distinct pathophysiological responses. Our findings demonstrate the overarching significance of the Aβ42:Aβ40 ratio in Aβ oligomers, challenging the traditional focus on Aβ42 in AD research.

Keywords: Alzheimer’s disease; Aβ oligomers; Aβ42:Aβ40; Raman microscopy; blood–brain barrier; lipid droplets.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research project was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation −414985841) and supported by the Cluster project ENABLE funded by the Hessian Ministry for Science and the Arts. The EUbOPEN project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 875510. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme, EFPIA.